The Woodlands, Texas, USA, September 1, 2026
Autonomix Medical, Inc. announced that two scientific abstracts featuring its transvascular nerve-targeting technology have been accepted for poster presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, scheduled for September 5–9 in Copenhagen, Denmark. The presentations will examine the potential of Autonomix’s investigational platform in two areas of interventional medicine: pain management for pancreatic adenocarcinoma and precision identification of neural structures. Both abstracts will be presented by Dr. Robert Schwartz, highlighting the company’s efforts to develop minimally invasive approaches for sensing and targeting nerves through the vascular system. The acceptance of the abstracts provides an opportunity for Autonomix to present its technology to the international interventional radiology community while advancing scientific discussion around image-guided and physiology-informed treatment approaches.
Autonomix Highlights Transvascular Nerve Technology
The first presentation, titled “Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation,” focuses on the potential use of radiofrequency (RF) energy-based ablation to denervate nerves associated with pain caused by pancreatic adenocarcinoma. Pancreatic cancer can be associated with severe and difficult-to-manage pain, creating a significant need for additional minimally invasive treatment strategies. Autonomix is investigating whether its catheter-based platform can facilitate targeted access to neural structures through the vasculature and deliver energy-based treatment to selected nerves. The long-term analysis to be presented at CIRSE is therefore positioned around the potential role of transvascular nerve denervation as an approach for pain management. The company has stated that its initial development efforts are focused on pancreatic cancer pain, while the broader platform could potentially be evaluated across additional nervous-system-related conditions. The second poster, titled “Illuminating the Nervous System with Transvascular Precision-Guided Technology,” will address Autonomix’s efforts to improve the identification and mapping of neural structures. The company’s platform incorporates a catheter-based microchip sensing array designed to detect and differentiate neural signals. According to Autonomix, this technology is being developed to provide physicians with physiological information that could help identify relevant nerves during minimally invasive procedures. Such an approach could potentially support more precise procedural targeting by combining vascular access with neural sensing. The presentation is part of SPHAIRE, CIRSE’s platform focused on artificial intelligence and emerging technologies in interventional radiology, placing Autonomix’s work within a broader discussion of technology-enabled image-guided care.
CIRSE 2026 Showcases Minimally Invasive Innovation
The CIRSE 2026 Annual Congress will bring together professionals from the global interventional radiology community under the theme “Breaking barriers, expanding care.” The scientific program covers a broad range of interventional procedures, including arterial and venous interventions, interventional oncology, embolization, nonvascular interventions and neurointerventions. The congress will also feature clinical data, emerging technologies, hands-on training and multidisciplinary sessions focused on improving minimally invasive patient care. Autonomix’s two accepted posters fit this environment by examining technology designed to expand the ability to sense, map and treat peripheral nerves through transvascular approaches. For Autonomix, the CIRSE presentations represent an opportunity to build scientific visibility around a platform that combines neural sensing, vascular access and targeted therapy delivery. The company describes its technology as a potential platform for diagnosing and treating diseases involving the peripheral nervous system, with possible applications extending beyond pancreatic cancer pain to areas such as cardiology, hypertension and chronic pain management. However, these broader applications remain developmental possibilities rather than established clinical indications. Autonomix specifically states that its technology is investigational and has not yet been cleared for marketing in the United States.
Advertisement
Autonomix Advances Precision Neuromodulation Research
The scientific presentations also form part of Autonomix’s broader development strategy for precision nerve-targeted treatments. By seeking to identify neural signals and guide interventions through a transvascular route, the company aims to address limitations associated with locating and treating nerves during minimally invasive procedures. The research presented at CIRSE may contribute to understanding how physiological nerve information can be incorporated into treatment planning and procedural guidance. Continued clinical and preclinical development will be necessary to determine the safety, performance and potential clinical utility of the platform across its proposed applications. The acceptance of both abstracts underscores growing interest in technologies that could integrate real-time neural sensing with minimally invasive intervention. For interventional radiology and medical-device development, such technologies could eventually support more targeted procedures while potentially reducing unnecessary tissue disruption. At this stage, however, the CIRSE presentations should be viewed as scientific and developmental updates, rather than evidence of regulatory clearance or established clinical effectiveness. Autonomix’s ongoing research will be important in determining whether its transvascular platform can translate these technological concepts into clinically meaningful applications.
Source: Autonomix Medical press release
